Impact of Inflation Reduction Act and the Drug Price Negotiation Program in Oncology

EP: 1.Impact of Recent Policies on US Health Care System and Oncology Practice

EP: 2.Bridging Policy Change With Patient Access and Care Delivery in Oncology

EP: 3.Role of Pharmacy Benefit Managers in Oncology

EP: 4.Impact of Utilization Management Policies in Oncology

EP: 5.Challenges of Step Edits in Oncology

EP: 6.Understanding Gaps in Aligning Coverage Policy With Innovation in Oncology

EP: 7.Disconnect Between NCCN Guidelines and Coverage Decisions With BTK Inhibitors in CLL

EP: 8.Impact of Evidence-Coverage Misalignment on Patient Outcomes With BTK Inhibitors in CLL

EP: 9.Using Real-World Evidence of BTK Inhibitors to Inform Coverage Decisions in CLL

EP: 10.Balancing Black Box Warnings With Real-World Oncology Practice

EP: 11.Impact of Utilization Management on Physician Autonomy and Shared Decision-Making in Oncology

EP: 12.Shaping Oncology Policy Through Access and Safety Considerations

Now Viewing

EP: 13.Impact of Inflation Reduction Act and the Drug Price Negotiation Program in Oncology

EP: 14.Implications of IRA Drug Pricing Negotiations on BTK Inhibitors in CLL

EP: 15.The Future of Oncology Research in a Shifting Policy Landscape

Panelists discuss how the Inflation Reduction Act (IRA) introduces landmark changes to drug pricing through its negotiation program, reshaping oncology economics. They outline key provisions that enable Medicare to negotiate prices for high-cost therapies, with ripple effects across commercial markets.

While potentially beneficial for affordability, panelists caution that reduced margins may impact innovation, particularly in niche oncology research. They discuss the balance between controlling costs and maintaining incentives for continued development of life-saving drugs.

Overall, they agree that proactive engagement between policymakers and industry is crucial to implementing the IRA in ways that enhance access without stifling innovation.